Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ERH regulates type II interferon immune signaling through post-transcriptional regulation of JAK2 mRNA [4]

ABSTRACT: ERH regulates type II interferon immune signaling through post-transcriptional regulation of JAK2 mRNA [4]

PROVIDER: PRJNA1144903 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR30150100_1.fastq.gz	Fastqsanger.gz
	SRR30150100_2.fastq.gz	Fastqsanger.gz
	SRR30150101_1.fastq.gz	Fastqsanger.gz
	SRR30150101_2.fastq.gz	Fastqsanger.gz
	SRR30150102_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

ERH regulates type II interferon immune signaling through post-transcriptional regulation of JAK2 mRNA [3]

Project description:Type II interferon (IFNγ) signaling is essential for innate immunity and critical for effective immunological checkpoint blockade in cancer immunotherapy. Genetic screen identification of post-transcriptional regulators of this pathway has been challenging since such factors are often essential for cell viability. Here, we utilize our inducible CRISPR/Cas9 approach to screen for key post-transcriptional regulators of IFNγ signaling, and in this way identify ERH and the ERH-associated splicing and RNA export factors MAGOH, SRSF1, and ALYREF. Loss of these factors impairs post-transcriptional mRNA maturation of JAK2, a crucial kinase for IFNγ signaling, resulting in abrogated JAK2 protein levels and diminished IFNγ signaling. Further analysis highlights a critical role for ERH in preventing intron retention in AU-rich regions in specific transcripts, such as JAK2. This regulation is markedly different from previously described retention of GC-rich introns. Overall, these findings reveal that post-transcriptional JAK2 processing is a critical rate-limiting step for the IFNγ-driven innate immune response.

2024-08-22 | GSE274071 | GEO

ERH regulates type II interferon immune signaling through post-transcriptional regulation of JAK2 mRNA [2]

2024-08-22 | GSE274070 | GEO

ERH regulates type II interferon immune signaling through post-transcriptional regulation of JAK2 mRNA [1]

2024-08-22 | GSE274069 | GEO

ERH regulates type II interferon immune signaling through post-transcriptional regulation of JAK2 mRNA [4]

2024-08-22 | GSE274074 | GEO

ERH regulates type II interferon immune signaling through post-transcriptional regulation of JAK2 mRNA [1]

Project description:ERH regulates type II interferon immune signaling through post-transcriptional regulation of JAK2 mRNA [1]

| PRJNA1144894 | ENA

ERH regulates type II interferon immune signaling through post-transcriptional regulation of JAK2 mRNA [2]

Project description:ERH regulates type II interferon immune signaling through post-transcriptional regulation of JAK2 mRNA [2]

| PRJNA1144895 | ENA

ERH regulates type II interferon immune signaling through post-transcriptional regulation of JAK2 mRNA [3]

Project description:ERH regulates type II interferon immune signaling through post-transcriptional regulation of JAK2 mRNA [3]

| PRJNA1144896 | ENA

MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2

Project description:Immunotherapy revolutionized the treatment of advanced melanoma. As the pathways mediating resistance to immunotherapy are largely unknown, we conducted transcriptome profiling of pre-immunotherapy tumor biopsies from melanoma patients that received PD-1 blockade (n=36) or adoptive cell therapy with tumor infiltrating lymphocytes (n=37). We identified two melanoma-intrinsic mutually exclusive gene programs, which are controlled by interferon-γ and MYC, and determine immunotherapy outcome. MYC-overexpressing melanoma cells exhibited lower interferon-γ responsiveness, which was linked with JAK2 downregulation. Luciferase activity assays under the control of JAK2 promoter demonstrated reduced activity in MYC-overexpressing cells, which was reversible upon mutagenesis of MYC E-box binding sites in the JAK2 promoter. Moreover, silencing of MYC or its co-factor MAX with siRNA increased JAK2 expression and interferon-γ responsiveness of melanomas, while concomitantly enhancing the effector functions of T-cells co-incubated with MYC-overexpressing cells. Thus, we propose that MYC plays a pivotal role in immunotherapy resistance through downregulation of JAK2.

2023-04-24 | GSE160638 | GEO

MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2

Project description:MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2

| PRJNA673835 | ENA

Development of resistance to type II JAK2 inhibition in MPN depends on AXL kinase and is targetable

Project description:Purpose: Myeloproliferative neoplasms (MPN) dysregulate JAK2 signaling. Since clinical JAK2 inhibitors have limited disease-modifying effects, type II JAK2 inhibitors such as CHZ868 stabilizing inactive JAK2 and reducing MPN clones, gain interest. We studied whether MPN cells escape from type ll inhibition.Methods: MPN cells were continuously exposed to CHZ868. We used phosphoproteomic analyses and ATAC-/RNA-sequencing to characterize acquired resistance to type II JAK2 inhibition, and targeted candidate mediators in MPN cells and mice.Results: MPN cells showed increased IC50 and reduced apoptosis upon CHZ868 reflecting acquired resistance to JAK2 inhibition. Among >2500 differential phospho-sites, MAPK pathway activation was most prominent, while JAK2-STAT3/5 remained suppressed. Altered histone occupancy promoting AP-1/GATA binding motif exposure associated with upregulated AXL kinase and enriched RAS target gene profiles. AXL knockdown resensitized MPN cells and combined JAK2/AXL inhibition using bemcentinib or gilteritinib reduced IC50 to levels of sensitive cells. While resistant cells induced tumor growth in NSG mice despite JAK2 inhibition, JAK2/AXL inhibition largely prevented tumor progression. Since inhibitors of MAPK pathway kinases such as MEK are clinically used in other malignancies, we evaluated JAK2/MAPK inhibition with trametinib to interfere with AXL-MAPK-induced resistance. Tumor growth was halted similarly to JAK2/AXL inhibition and in a systemic cell line-derived mouse model, marrow infiltration was decreased supporting dependency on AXL-MAPK.Conclusions: We report on a novel mechanism of AXL-MAPK-driven escape from type II JAK2 inhibition, which is targetable at different nodes. This highlights AXL as mediator of acquired resistance warranting inhibition to enhance sustainability of JAK2 inhibition in MPN

2023-11-07 | PXD039419 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data